NCT06643936Active, not recruiting

E3 Diabetes - Closing the Gap in Diabetes Control

Source: ClinicalTrials.gov · Last updated 15 Oct 2026

Brief summary (registry, in English)

This study aims to decrease the racial gap in type 2 diabetes control in African American and Latinx patients in Rush University Medical Center clinics.

Status (registry): Active, not recruiting
Study type: Interventional
Enrollment: 150 (estimated)
First submitted: 14 Oct 2024
Start date: 18 Nov 2024
Primary completion date: 31 Dec 2026
Lead sponsor: Rush University Medical Center
Diseases: Type 2 diabetes
NCT number: NCT06643936

What you commit to

Study type: Interventional
Planned participants: 150
From 18 Nov 2024 to the primary completion date, 31 Dec 2026
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

Patient has Type 1 Diabetes
Patient is already participating in another remote diabetes monitoring program
Patient has already participated in the E3 hypertension program

Other

Patient is not interested in participating in the program

Who the study is looking for

Adults 18 years and older
African American and/or Latinx
Uncontrolled Type 2 Diabetes, A1C \>/= 8.0 within the last 3 months
Following with Rush primary care provider in eligible Rush primary care clinics
Access to cellphone

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
Rush University Medical Center Coordinator of this site? Confirm its status	Chicago	United States	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.